Isoniazid, rifampicin (Rifizid)
Isoniazid, rifampicin
Medicine Developers International (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Medicine Developers International (Pty) Ltd
- Registrations
- 1
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Rifizid 300/150 EACH TABLET CONTAINS ISONIAZID 150,0 mg RIFAMPICIN 300,0 mg | 300/150 | A400543A40/20.2.3/0543 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Isoniazid, rifampicin
S4: Isoniazid
Consolidated Schedules 06 July 2026, line 6819
S4: Rifampicin
Consolidated Schedules 06 July 2026, line 7802
Pharmacological class: Tuberculostatics. (class 20.2.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.